NCT03605836: A reported trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03605836 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 16, 2019 |
| Completion date | May 14, 2020 |
| Required reporting date | May 14, 2021, midnight |
| Actual reporting date | May 10, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |